



## Prescription Pharmaceutical Products

PRODUCT	INDICATION <sup>1,2</sup>	TERRITORY <sup>3</sup>					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
<b>Oncology/Hematology</b>							
<b>Minjuvi</b> <sup>®</sup>	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	N/A <sup>4</sup>	Q1-24	Submitted	Submitted	Submitted	Incyte
<b>Pemazyre</b> <sup>®</sup>	Metastatic cholangiocarcinoma	N/A <sup>4</sup>	Submitted	Submitted	Submitted	Submitted	Incyte
<b>Akynzeo</b> <sup>®</sup>	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22	N/A <sup>4</sup>	N/A <sup>4</sup>	Helsinn
<b>Aloxi</b> <sup>®</sup>	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Q4-22	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	Helsinn
<b>Tavalisse</b> <sup>®</sup> (fostamatinib)	Treatment of chronic immune thrombocytopenia	N/A <sup>4</sup>	Submitted	Pre-registration	Submitted	Submitted	Rigel
<b>Trelstar</b> <sup>®</sup>	Advanced prostate cancer	Q2-20	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	Debiopharm
<b>Vidaza</b> <sup>®</sup>	Myelodysplastic syndrome	N/A <sup>4</sup>	Q2-10	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	BMS
<b>Abraxane</b> <sup>®</sup>	Metastatic pancreatic cancer	N/A <sup>4</sup>	Q4-17	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	BMS
<b>Halaven</b> <sup>®</sup>	Metastatic breast cancer and soft tissue sarcoma	N/A <sup>4</sup>	Q4-17	Q4-19	Q2-22	N/A <sup>4</sup>	Eisai
<b>Lenvima</b> <sup>®</sup>	Differentiated thyroid cancer and unresectable hepatocellular carcinoma	N/A <sup>4</sup>	Q4-17		Q1-22	N/A <sup>4</sup>	Eisai
<b>Lenvima</b> <sup>®</sup>	Advanced renal cell cancer	N/A <sup>4</sup>	Q4-17			N/A <sup>4</sup>	Eisai
<b>BGx</b>							
<b>Ladevina</b> <sup>®</sup>	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Own
<b>Ladevina</b> <sup>®</sup>	Mantle Cell Lymphoma; follicular lymphoma			2011			Own
<b>Zyvalix</b> <sup>®</sup>	Metastatic prostate cancer			2014	Q2-18		Own
<b>Karfib</b> <sup>®</sup>	Relapsed or refractory multiple myeloma			Q4-19	Approved		Own
<b>Leprid</b> <sup>®</sup>	Palliative treatment of advanced prostate cancer			2007			Own
<b>Rembre</b> <sup>®</sup>	Chronic myeloid leukemia			2013	Q1-22		Own
<b>Palbocil</b> <sup>®</sup> , <b>Bapocil</b> <sup>®</sup>	Breast cancer			Q1-23	Submitted		Own
<b>Xetrane</b> <sup>®</sup>	Multiple myeloma			Q2-19	Submitted		Own
<b>Xetrane</b> <sup>®</sup>	AIDS-related Kaposi sarcoma			Q2-22			Own

<sup>1</sup> The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

<sup>2</sup> The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.

<sup>3</sup> The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

<sup>4</sup> Knight does not have the commercial rights in these territories.



PRODUCT	INDICATION <sup>1,2</sup>	TERRITORY <sup>3</sup>					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
<b>Infectious Diseases</b>							
<b>Ambisome®</b>	Invasive fungal infection	N/A <sup>4</sup>	1997	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	Gilead
<b>Cresemba®</b>	Invasive fungal infection	N/A <sup>4</sup>	Q2-20	Q3-19	Q3-19	Q2-19	Basilea
<b>Impavido®</b>	Leishmaniasis						Own
<b>BGx</b>							
<b>Dolufevir®</b>	HIV infection			Q2-21			Own
<b>Other Specialty</b>							
<b>Exelon®</b>	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Own
<b>Ibsrela®</b>	IBS-C	Q1-21	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	Ardelyx
<b>Salofalk®</b>	Ulcerative colitis	N/A <sup>4</sup>	N/A <sup>4</sup>	2007	Pre-2019	N/A <sup>4</sup>	Dr. Falk
<b>Ursofalk®</b>	Primary biliary cirrhosis	N/A <sup>4</sup>	N/A <sup>4</sup>	2007	Pre-2019	N/A <sup>4</sup>	Dr. Falk
<b>Imvexxy®</b>	Moderate-to-severe dyspareunia	Q1-24	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	TXMD
<b>Bijuva®</b>	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	TXMD
<b>BGx</b>							
<b>Fibridoner®</b>	Idiopathic pulmonary fibrosis			2017			Own

<sup>1</sup> The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

<sup>2</sup> The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.

<sup>3</sup> The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

<sup>4</sup> Knight does not have the commercial rights in these territories.



## Pipeline and Products in Early Launch Stage

The Company expects that its pipeline and products in early launch stage could achieve total revenues of over \$150,000,000 combined in their peak years. The products in early launch stage are within three years from the commercial launch date on a country by country basis.

PRODUCT	INDICATION OR THERAPEUTIC AREA <sup>1,2</sup>	TERRITORY <sup>3</sup>					LAUNCH / EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	
<b>Oncology/Hematology</b>							
<b>Minjuvi® (tafasitamab)</b>	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	N/A <sup>4</sup>	Q1-24	Submitted	Submitted	Submitted	2024 -2026
<b>Pemigatinib</b>	Metastatic cholangiocarcinoma	N/A <sup>4</sup>	Submitted	Submitted	Submitted	Submitted	2025-2026
<b>Fostamatinib</b>	Treatment of chronic immune thrombocytopenia	N/A <sup>4</sup>	Submitted	Pre-registration	Submitted	Submitted	2025-2026
<b>Bapocil®<sup>1</sup></b>	Breast Cancer				Submitted		2025
<b>Xetrane®<sup>1</sup></b>	Multiple myeloma				Submitted		2025
<b>Karfib®<sup>1</sup></b>	Relapsed or refractory multiple myeloma				Approved		2025
<b>Rembre®<sup>1</sup></b>	Chronic myeloid leukemia				Q1-22		N/A
<b>O501<sup>1</sup></b>	Oncology/Hematology			Submitted			2025
<b>O502<sup>1</sup></b>	Oncology/Hematology			Submitted			2025
<b>H401</b>	Oncology/Hematology	N/A <sup>4</sup>	Development	N/A <sup>4</sup>	Development	Development	2028
<b>H402</b>	Oncology/Hematology		Development				2028 - 2029
<b>Other Specialty</b>							
<b>Imvexxy®</b>	Moderate-to-severe dyspareunia	Q1-24	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	2024
<b>Bijuva®</b>	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	2024
<b>IPX203</b>	Attention-Deficit Hyperactivity Disorder (ADHD)	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	2027-2028
<b>Qelbree™</b>	Attention-Deficit Hyperactivity Disorder (ADHD)	Pre-registration	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	N/A <sup>4</sup>	2026-2027
<b>Jornay PM™</b>	Parkinson's disease	Submitted				Pre-registration	2025-2028
<b>C401 (Neurology)</b>	Other Specialty				Submitted		2025 - 2026
<b>C402/403 (Neurology)</b>	Other Specialty	N/A <sup>4</sup>	Submitted		Development	Pre-registration	2026 - 2027

<sup>1</sup> The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

<sup>2</sup> The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.

<sup>3</sup> The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

<sup>4</sup> Knight does not have the commercial rights in these territories.